New Delhi : Observed annually on June 27, National HIV Testing Day recognizes and addresses ongoing disparities related to HIV infection. This day serves as a powerful reminder of the ongoing battle against HIV and the importance of awareness, education, and support for those affected. Routine HIV testing and increased accessibility to tests are crucial in the fight against HIV, says GlobalData.

Testing is pivotal in ending the HIV epidemic, making it a central theme for this year’s World AIDS Day. The COVID-19 pandemic initially slowed HIV testing rates as public health efforts focused on COVID-19, but recent trends indicate a resilient comeback. Public health initiatives, increased awareness, and accessible testing facilities contribute to this positive shift.

According to the GlobalData HIV Tests SKU Tracker, an estimated 18.6 million tests were sold to hospitals in the US in 2020 during the pandemic peak, recovering to 22.9 million tests in 2022.

Selena Yu, senior medical analyst at GlobalData, states, “GlobalData expects this trend to continue in 2023 and into 2024. Globally, the WHO has been pushing to decrease HIV prevalence, which starts with reducing the spread and highlights the importance of frequent HIV testing, especially for higher-risk individuals.”

GlobalData’s report, “Human Immunodeficiency Virus (HIV) Tests 2015-2033,” indicates the global HIV test market value increased by 1.86 per cent from 2015-2023, growing from $1.37 billion to $1.59 billion, and is forecasted to exceed $2 billion by 2033. Roche holds the largest market share globally at 14.6 per cent, with Abbott in second at 11.9 per cent and Siemens Healthineers third at 9.2 per cent.

Yu concludes, “The HIV test market continues to evolve as self-testing becomes a popular option. Despite campaigns to destigmatize HIV/AIDS, at-risk individuals still feel uncomfortable getting tested. Positive test results require follow-up testing by a healthcare professional. An important player in HIV self-testing is Oraquick, a subsidiary of Orasure, as it’s the only FDA-approved rapid HIV self-test currently available in the US market. Private testing options may incentivize at-risk individuals to test more frequently.”

  • Published On Jun 27, 2024 at 12:26 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles

Scan to download App